3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030

952
Comment
10

3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030

Motley Fool2022-05-29

Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

952

Report

Comment

Jess261
·2022-05-30
Okay
Reply
Like
Report
VivianChua
·2022-05-30
Ok
Reply
Like
Report
YueShan
·2022-05-30
Good⭐⭐⭐
Reply
Like
Report
Ragz
·2022-05-30
Keep for 8 years [OMG]
Reply
1
Report
Dragonbody
·2022-05-30
[Miser] [Miser]
Reply
2
Report
Alfred1007
·2022-05-30
Teladoc maybe
Reply
2
Report
Ameliakoh
·2022-05-30
Like pls 🙏
Reply
6
Report
Shirley Soh
·2022-05-30
Ok
Reply
1
Report
Fayedea
·2022-05-30
Great
Reply
2
Report
Ktkw
·2022-05-30
Good
Reply
3
Report
LWayn
·2022-05-30
Like pls
Reply
2
Report
DarkFate
·2022-05-30
Like
Reply
2
Report
Chitz
·2022-05-30
Like
Reply
2
Report
Seah CL
·2022-05-30
K
Reply
3
Report
TLC88
·2022-05-30
Ok
Reply
4
Report
MeowTamara
·2022-05-30
10 years
Reply
3
Report
Kiki19
·2022-05-30
Please like
Reply
3
Report
FT585
·2022-05-30
Like
Reply
2
Report
SCLIEW
·2022-05-30
666
Reply
2
Report
hphoa
·2022-05-30
Good...
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2238953846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-29 16:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2238953846","market":"us","top_or_hot":-1,"title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","media":"Motley Fool","content":"<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","article_id":"2238953846","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","pubTimestamp":1653811796,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4566":"资本集团","BK4167":"医疗保健技术","BK4581":"高盛持仓","QNETCN":"纳斯达克中美互联网老虎指数","MELI":"MercadoLibre","BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","BK4122":"互联网与直销零售","BK4567":"ESG概念","TDOC":"Teladoc Health Inc."},"translate_title":"3种到2030年可以轻松将1万美元变成5万美元的股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TDOC":0.9,"MELI":0.83,"QNETCN":0.6},"content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":9024523615,"gmtCreate":1653888682337,"gmtModify":1676535358455,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024523615","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024562624,"gmtCreate":1653887611468,"gmtModify":1676535358159,"author":{"id":"3580011914778910","authorId":"3580011914778910","name":"VivianChua","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024562624","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024538097,"gmtCreate":1653882857319,"gmtModify":1676535357273,"author":{"id":"3583033297199166","authorId":"3583033297199166","name":"YueShan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Good⭐⭐⭐","listText":"Good⭐⭐⭐","text":"Good⭐⭐⭐","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024538097","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024254284,"gmtCreate":1653876906848,"gmtModify":1676535356021,"author":{"id":"4114498221568562","authorId":"4114498221568562","name":"Ragz","avatar":"https://community-static.tradeup.com/news/b4ff9d535326b2e5c1e196c2eaee90d6","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"Keep for 8 years&nbsp;[OMG]&nbsp;","listText":"Keep for 8 years&nbsp;[OMG]&nbsp;","text":"Keep for 8 years [OMG]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024254284","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024294909,"gmtCreate":1653872203701,"gmtModify":1676535354374,"author":{"id":"4109052217286120","authorId":"4109052217286120","name":"Dragonbody","avatar":"https://community-static.tradeup.com/news/8c619fa4bf1941f68f7764c4f6441991","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024294909","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024295563,"gmtCreate":1653872171552,"gmtModify":1676535354391,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Teladoc maybe","listText":"Teladoc maybe","text":"Teladoc maybe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024295563","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024298086,"gmtCreate":1653871874545,"gmtModify":1676535354229,"author":{"id":"3574754838536636","authorId":"3574754838536636","name":"Ameliakoh","avatar":"https://static.tigerbbs.com/4a747ab791603fb0a649736b10ec7454","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls 🙏","listText":"Like pls 🙏","text":"Like pls 🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024298086","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024647210,"gmtCreate":1653870271230,"gmtModify":1676535353699,"author":{"id":"4100664503126340","authorId":"4100664503126340","name":"Shirley Soh","avatar":"https://community-static.tradeup.com/news/784ec5f33096066f43c22d219e548bac","vip":1,"crmLevel":8,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024647210","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024642970,"gmtCreate":1653870174490,"gmtModify":1676535353575,"author":{"id":"4087523982151170","authorId":"4087523982151170","name":"Fayedea","avatar":"https://static.tigerbbs.com/f9d26a7d632140dba3255747fafc07d3","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024642970","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024631860,"gmtCreate":1653866602250,"gmtModify":1676535351994,"author":{"id":"3564917665277560","authorId":"3564917665277560","name":"Ktkw","avatar":"https://static.tigerbbs.com/c3b319f06c5f5672546acc9d6f02dec1","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024631860","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024631051,"gmtCreate":1653866594073,"gmtModify":1676535351987,"author":{"id":"3576155950532966","authorId":"3576155950532966","name":"LWayn","avatar":"https://static.itradeup.com/news/a1494fdde392e14853a112872a51213e","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024631051","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024694443,"gmtCreate":1653866272082,"gmtModify":1676535351886,"author":{"id":"4097476142152970","authorId":"4097476142152970","name":"DarkFate","avatar":"https://static.tigerbbs.com/a22f6ff84fe185b6d3ad31b8673302d8","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024694443","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024690614,"gmtCreate":1653865816638,"gmtModify":1676535351687,"author":{"id":"3574934277926519","authorId":"3574934277926519","name":"Chitz","avatar":"https://static.tigerbbs.com/988984eee397d7e772b978815d9b162e","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024690614","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024690368,"gmtCreate":1653865799154,"gmtModify":1676535351680,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024690368","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024605600,"gmtCreate":1653865599900,"gmtModify":1676535351612,"author":{"id":"3579644221346646","authorId":"3579644221346646","name":"TLC88","avatar":"https://static.tigerbbs.com/70e92e6f93d89c4be15661304799bff0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024605600","repostId":2238953846,"repostType":2,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024601739,"gmtCreate":1653865352721,"gmtModify":1676535351538,"author":{"id":"4091417768263030","authorId":"4091417768263030","name":"MeowTamara","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"10 years&nbsp;","listText":"10 years&nbsp;","text":"10 years","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024601739","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024877503,"gmtCreate":1653864817902,"gmtModify":1676535351207,"author":{"id":"4097387260130260","authorId":"4097387260130260","name":"Kiki19","avatar":"https://static.itradeup.com/news/1330ce44324f235bf8d1fd1b32e7b559","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Please like&nbsp;","listText":"Please like&nbsp;","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024877503","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024877845,"gmtCreate":1653864795487,"gmtModify":1676535351207,"author":{"id":"3562726241279787","authorId":"3562726241279787","name":"FT585","avatar":"https://static.tigerbbs.com/734b50619b12425294cb4715814bdedb","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024877845","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024875486,"gmtCreate":1653864675245,"gmtModify":1676535351220,"author":{"id":"4092970777728640","authorId":"4092970777728640","name":"SCLIEW","avatar":"https://static.tigerbbs.com/5da553e4d3d35db75d1caae023ca8a03","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024875486","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9024875103,"gmtCreate":1653864647602,"gmtModify":1676535351162,"author":{"id":"3578790486524477","authorId":"3578790486524477","name":"hphoa","avatar":"https://community-static.tradeup.com/news/28a11e936497493af7ee5ccdc32238a3","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good...&nbsp;","listText":"Good...&nbsp;","text":"Good...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024875103","repostId":2238953846,"repostType":4,"repost":{"id":"2238953846","pubTimestamp":1653811796,"share":"https://www.laohu8.com/m/news/2238953846?lang=&edition=full","pubTime":"2022-05-29 16:09","market":"us","language":"en","title":"3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2238953846","media":"Motley Fool","summary":"A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.","content":"<html><head></head><body><p>Quintupling just has a nice ring to it. There&#39;s not an investor around who wouldn&#39;t like to see their money grow by five times or more.</p><p>Finding stocks that can achieve the goal is easier said than done, though. That&#39;s especially the case if you&#39;re wanting huge gains within only a few years. But it&#39;s not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.</p><h2>1. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a></h2><p><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health</a> could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.</p><p>Of course, getting back to those levels isn&#39;t so simple. Teladoc must first convince investors that it&#39;s able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc&#39;s business actually appears to be in pretty good shape.</p><p>That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company&#39;s bottom line improved year over year. And although Teladoc&#39;s full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.</p><p>Teladoc continues to win new customers. It&#39;s only in the early stages of rolling out the Primary360 virtual primary care service. The company&#39;s addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn&#39;t a slam dunk to quintuple by the end of the decade. However, it isn&#39;t too far-fetched a proposition at all.</p><h2>2. <a href=\"https://laohu8.com/S/NVCR\">Novocure</a></h2><p>Turning $10,000 into $50,000 by 2030 could be too pessimistic a goal for <a href=\"https://laohu8.com/S/NVCR\">Novocure</a>. Sure, the stock is down more than 60% since last July as the company&#39;s revenue growth has slowed. But Novocure has multiple catalysts on the way.</p><p>The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.</p><p>Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.</p><p>Novocure estimates that these additional indications represent a market opportunity that&#39;s <i>14 times larger</i> than its current market opportunity in approved indications. If the company&#39;s late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.</p><h2>3. <a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a></h2><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre&#39;s business continues to perform well.</p><p>The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.</p><p>More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company&#39;s fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.</p><p>MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company&#39;s Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, &#34;We&#39;re very excited about the opportunity.&#34;</p><p>Wall Street&#39;s consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company&#39;s growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-29 16:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","MELI":"MercadoLibre","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4581":"高盛持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","QNETCN":"纳斯达克中美互联网老虎指数","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2022/05/28/3-stocks-that-could-easily-turn-10000-into-50000-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238953846","content_text":"Quintupling just has a nice ring to it. There's not an investor around who wouldn't like to see their money grow by five times or more.Finding stocks that can achieve the goal is easier said than done, though. That's especially the case if you're wanting huge gains within only a few years. But it's not impossible to find promising candidates. Here are three stocks that could easily turn $10,000 into $50,000 by 2030.1. Teladoc HealthTeladoc Health could deliver a 5x return simply by returning to where its shares traded less than a year ago. Since last summer, the telemedicine stock has plunged close to 80%.Of course, getting back to those levels isn't so simple. Teladoc must first convince investors that it's able to deliver strong revenue growth and achieve profitability. I think the company has a good shot at doing both. Despite a huge net loss and reducing its full-year guidance for 2022, Teladoc's business actually appears to be in pretty good shape.That big loss was due to a goodwill impairment primarily related to the acquisition of Livongo. Excluding this write-off, the company's bottom line improved year over year. And although Teladoc's full-year outlook is lower than it was previously, it still expects revenue to grow in the ballpark of 20%.Teladoc continues to win new customers. It's only in the early stages of rolling out the Primary360 virtual primary care service. The company's addressable market is massive -- over $260 billion in the U.S. alone. Teladoc certainly isn't a slam dunk to quintuple by the end of the decade. However, it isn't too far-fetched a proposition at all.2. NovocureTurning $10,000 into $50,000 by 2030 could be too pessimistic a goal for Novocure. Sure, the stock is down more than 60% since last July as the company's revenue growth has slowed. But Novocure has multiple catalysts on the way.The company has already won U.S. regulatory approval for its Tumor Treating Fields (TTFields) device in treating glioblastoma multiforme (an aggressive type of brain cancer) and mesothelioma. However, Novocure thinks that its method of using electric fields to disrupt the division of tumor cells can work in other types of cancer as well.Results from a late-stage study of TTFields in treating non-small cell lung cancer should be announced later this year. In 2023, Novocure expects to report data from pivotal studies targeting ovarian cancer and brain metastases. The following year, results from another phase 3 study of TTFields in treating pancreatic cancer should be available.Novocure estimates that these additional indications represent a market opportunity that's 14 times larger than its current market opportunity in approved indications. If the company's late-stage clinical studies go well, the stock should have a pretty good shot at delivering a 5x return or greater within the next eight years.3. MercadoLibreMercadoLibre is another beaten-down stock that still has tremendous long-term potential. Shares of the Latin American e-commerce leader have dropped close to 60% since the third quarter of 2021. However, MercadoLibre's business continues to perform well.The company generated record net revenue in the first quarter of 2022. It posted a small profit, a huge improvement from the net losses in the previous quarter and in the prior-year period.More importantly, MercadoLibre is only scratching the surface of its opportunity. E-commerce market penetration rates in Latin America remain low. The company's fintech business has a significant growth runway as well. Many people in the countries served by MercadoLibre have no or limited access to traditional financial services.MercadoLibre could also grow by expanding into adjacent markets. Osvaldo Gimenez, CEO of the company's Mercado Pago unit, stated in the Q1 conference call that a pilot of a payroll service is in its early stages. He added, \"We're very excited about the opportunity.\"Wall Street's consensus 12-month price target for MercadoLibre is nearly double its current share price. I think that the company's growth potential in e-commerce, fintech, and new businesses just might enable the stock to turn an initial investment of $10,000 into $50,000 by 2030.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":952,"commentSize":0,"repostSize":0,"favoriteSize":10,"likeStatus":false,"favoriteStatus":false}}